4-(4-{3-[6-Methoxy-4-(4-nitro-phenylamino)-quinazolin-7-yloxy]-propoxy}-phenyl)-[1,2]dithiole-3-thione

ID: ALA4793333

Chembl Id: CHEMBL4793333

PubChem CID: 162673491

Max Phase: Preclinical

Molecular Formula: C27H22N4O5S3

Molecular Weight: 578.70

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1cc2c(Nc3ccc([N+](=O)[O-])cc3)ncnc2cc1OCCCOc1ccc(-c2cssc2=S)cc1

Standard InChI:  InChI=1S/C27H22N4O5S3/c1-34-24-13-21-23(28-16-29-26(21)30-18-5-7-19(8-6-18)31(32)33)14-25(24)36-12-2-11-35-20-9-3-17(4-10-20)22-15-38-39-27(22)37/h3-10,13-16H,2,11-12H2,1H3,(H,28,29,30)

Standard InChI Key:  SBNRVMRRLZKZTI-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4793333

    ---

Associated Targets(Human)

EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Egfr Epidermal growth factor receptor erbB1 (106 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 578.70Molecular Weight (Monoisotopic): 578.0752AlogP: 7.66#Rotatable Bonds: 11
Polar Surface Area: 108.64Molecular Species: NEUTRALHBA: 11HBD: 1
#RO5 Violations: 3HBA (Lipinski): 9HBD (Lipinski): 1#RO5 Violations (Lipinski): 2
CX Acidic pKa: CX Basic pKa: 4.58CX LogP: 6.55CX LogD: 6.55
Aromatic Rings: 5Heavy Atoms: 39QED Weighted: 0.06Np Likeness Score: -0.90

References

1. Zheng YG,Zhang WQ,Meng L,Wu XQ,Zhang L,An L,Li CL,Gao CY,Xu L,Liu Y.  (2020)  Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (HS) donors as potent EGFR inhibitors against L858R resistance mutation.,  202  [PMID:32619886] [10.1016/j.ejmech.2020.112522]

Source